Abstract:Abstract Alopecia is classified into nonscarring, such as alopecia areata, and scarring variants, including lichen planopilaris and frontal fibrosing alopecia. Treatment options are limited and there are restrictions on what is available on the National Health Service (NHS). Therefore, many patients require wigs or hairpieces as the mainstay of their management. Significant psychological burden has been associated with alopecia, and the use of wigs can have a positive impact on patients’ wellbeing. Montgomery et al. highlighted the unequal NHS wig provision (Montgomery K, White C, Thompson A. A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia. BMJ Open 2017; 7: e015468). This has led to the recommended ‘Charter for best practice for NHS wig provision’ by Alopecia UK and the British Association of Dermatologists and British Hair and Nail Society published in June 2022. They propose that all patients with alopecia should be able to access a wig via NHS prescription that is appropriate for their skin and hair colour, age and preference. Despite this, discrepancies exist in how wigs are funded in different regions and trusts. All our wig prescriptions are incurred by each department. Due to inflation these costs are rising. This has led to our department’s review of budgets and current prescribing practices. Our hospital’s overall gross cost of wig orders was £193 403 in 1 year. Our aim was to establish the wig prescribing practices in a single centre, which also provides a specialist hair clinic service, and the costs associated with current practices. We reviewed all wig prescriptions throughout our hospital over 12 months. We collected the following parameters: prescribing department, age, sex, diagnosis, number and type of wigs per year, cost per prescription and patient’s address. Patients who were seen in our hair clinic also had psychology-related scores reviewed. In total 324 prescriptions were issued to 200 patients with a median age of 52 years (range 4–87). There was a female predominance (97.5%). Nonscarring alopecia accounted for 57.7%. Overall, 60.5% of the prescriptions issued were for acrylic wigs, with the remainder prescribed human hair wigs. Prescriptions for out-of-area patients accounted for 69.1%. Psychological assessment using validated questionnaires including Dermatology Life Quality Index, Patient Health Questionnaire-9 and General Anxiety Disorder-7 were collected from patients’ initial consultations compared with their current scores. Wigs are an essential treatment for all patients with alopecia. Our results demonstrate the level of demand, the variety in diagnoses and a vast age range. Targeted treatments for alopecia areata are currently unavailable on the NHS; therefore, access to wigs remains vital in its management. Further work is required to ensure equitable NHS wig prescribing; we support Getting it Right First Time’s ongoing review of this.

British Hair and Nail SocietyOral presentationsBH01 (P087) The British Hair and Nail Society present a review of our national grand round of challenging hair disorders and the benefits to the wider British Association of Dermatologists membership

P087 The British Hair and Nail Society present a review of our national grand round of challenging hair disorders and the benefits to the wider British Association of Dermatologists membership

P112 The British Hair and Nail Society present a review of our national grand round of challenging nail conditions and the benefits to the wider British Association of Dermatologists membership

BH13 Current wig prescribing practices and financial evaluation in a National Health Service foundation trust: lessons learnt and future challenges

Patients' experiences of primary healthcare and dermatology provision for alopecia

P031 Experience from a UK dermatology regional virtual biologics and high-cost drugs multidisciplinary team

BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists

Invasive Scalp Melanoma: Role for Enhanced Detection Through Professional Training

Current wig prescribing practices and financial evaluation in an NHS Foundation Trust: Lessons learnt and future challenges

BH03 Do patients with afro-textured hair who are experiencing hair loss feel understood by their dermatologists? A cross-sectional study

A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders

Dermoscopy of Hair and Scalp Disorders (Trichoscopy) in Skin of Color - A Systematic Review by the International Dermoscopy Society "Imaging in Skin of Color" Task Force

BH10 Unequal National Health Service wig provision: toupée or no toupée, that is the question?

Teledermatology & Digital Dermatology SymposiumOral presentationsBT01 Developing a national artificial intelligence-assisted skin cancer pathway

The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata

Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase‐III trials and the real‐life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022

A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)

A practical guide to the standardisation of hair loss photography for clinicians

Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series

Morphological Approach to Hair Disorders

Psychological Aspects of Hair Disorders: Consideration for Dermatologists, Cosmetologists, Aesthetic, and Plastic Surgeons